First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes

First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes

Abstract Background Type 1 diabetes (T1D) is a CD4+ T cell-driven autoimmune disease characterized by the destruction of insulin-producing pancreatic β-cells by CD8+ T cells. Achieving glycemic targets in T1D remains challenging in clinical practice; new treatments aim to halt autoimmunity and prolo...

Full description

Bibliographic Details
Main Authors: Jean Van Rampelbergh, Peter Achenbach, Richard David Leslie, Mohammad Alhadj Ali, Colin Dayan, Bart Keymeulen, Katharine R. Owen, Martin Kindermans, Frédéric Parmentier, Vincent Carlier, Roxana R. Ahangarani, Evelien Gebruers, Nicolas Bovy, Luc Vanderelst, Marcelle Van Mechelen, Pierre Vandepapelière, Christian Boitard
Format: Article
Language:English
Published: BMC 2023-05-01
Series:BMC Medicine
Subjects:
Type 1 diabetes
Immunotherapy
T cells
Beta-cells
Clinical study
Safety
Online Access:https://doi.org/10.1186/s12916-023-02900-z

Internet

https://doi.org/10.1186/s12916-023-02900-z

Similar Items